52 related articles for article (PubMed ID: 29031068)
1. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
Xu Z; Hu W; Wang Z; Gou S
Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068
[TBL] [Abstract][Full Text] [Related]
2. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery.
Zheng YR; Suntharalingam K; Johnstone TC; Yoo H; Lin W; Brooks JG; Lippard SJ
J Am Chem Soc; 2014 Jun; 136(24):8790-8. PubMed ID: 24902769
[TBL] [Abstract][Full Text] [Related]
3. Platinum(IV) Complexes of
Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
[TBL] [Abstract][Full Text] [Related]
4. Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions.
Navas F; Chocarro-Calvo A; Iglesias-Hernández P; Fernández-García P; Morales V; García-Martínez JM; Sanz R; De la Vieja A; García-Jiménez C; García-Muñoz RA
J Med Chem; 2024 Apr; 67(8):6410-6424. PubMed ID: 38592014
[TBL] [Abstract][Full Text] [Related]
5. High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.
Peng X; Li Y; Qu J; Jiang L; Wu K; Liu D; Chen Y; Peng J; Guo Y; Cao X
Eur J Med Chem; 2024 May; 271():116405. PubMed ID: 38678823
[TBL] [Abstract][Full Text] [Related]
6. Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance.
Wang M; Li G; Jiang G; Cai J; Liu Z; Huang R; Huang X; Wang H
J Med Chem; 2024 Apr; 67(8):6218-6237. PubMed ID: 38573870
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide (NO) releasing poly ADP-ribose polymerase 1 (PARP-1) inhibitors targeted to glutathione S-transferase P1-overexpressing cancer cells.
Maciag AE; Holland RJ; Kim Y; Kumari V; Luthers CE; Sehareen WS; Biswas D; Morris NL; Ji X; Anderson LM; Saavedra JE; Keefer LK
J Med Chem; 2014 Mar; 57(6):2292-302. PubMed ID: 24521039
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative Activity of Pt(IV) Conjugates Containing the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ketoprofen and Naproxen
Ravera M; Zanellato I; Gabano E; Perin E; Rangone B; Coppola M; Osella D
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31238499
[TBL] [Abstract][Full Text] [Related]
9. Structure-Guided Design of Ferritin-Platinum Prodrugs for Targeted Therapy of Esophageal Squamous Cell Carcinoma.
Jiang B; Chen X; Wang S; Wang S; Ma S; Lu Y; Ma L; Liang Q; Xiao H; Zhang L; Yan X; Fan K
ACS Nano; 2024 Apr; 18(17):11217-11233. PubMed ID: 38627234
[TBL] [Abstract][Full Text] [Related]
10. A Comparative Study of the Anticancer Activity and PARP-1 Inhibiting Effect of Benzofuran-Pyrazole Scaffold and Its Nano-Sized Particles in Human Breast Cancer Cells.
Anwar MM; Abd El-Karim SS; Mahmoud AH; Amr AEE; Al-Omar MA
Molecules; 2019 Jun; 24(13):. PubMed ID: 31261939
[TBL] [Abstract][Full Text] [Related]
11. Gemfibrozil-Platinum(IV) Precursors for New Enhanced-Starvation and Chemotherapy In Vitro and In Vivo.
Song XQ; Guo X; Ding YX; Han YX; You ZH; Song Y; Yuan Y; Li L
J Med Chem; 2024 May; 67(9):7033-7047. PubMed ID: 38634331
[TBL] [Abstract][Full Text] [Related]
12. Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
Ononye SN; Vanheyst MD; Giardina C; Wright DL; Anderson AC
Bioorg Med Chem; 2014 Apr; 22(7):2188-93. PubMed ID: 24613456
[TBL] [Abstract][Full Text] [Related]
13. Multi-functionalization of reduced graphene oxide nanosheets for tumor theragnosis: Synthesis, characterization, enzyme assay, in-silico study, radiolabeling and in vivo targeting evaluation.
Sakr TM; Elsabagh MF; Fayez H; Sarhan MO; Syam YM; Anwar MM; Motaleb MA; Zaghary WA
Daru; 2024 Jun; 32(1):77-95. PubMed ID: 38072913
[TBL] [Abstract][Full Text] [Related]
14. Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance.
Petruzzella E; Sirota R; Solazzo I; Gandin V; Gibson D
Chem Sci; 2018 May; 9(18):4299-4307. PubMed ID: 29780561
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties.
Salvador LA; Park H; Al-Awadhi FH; Liu Y; Kim B; Zeller SL; Chen QY; Hong J; Luesch H
ACS Med Chem Lett; 2014 Aug; 5(8):905-10. PubMed ID: 25147612
[TBL] [Abstract][Full Text] [Related]
16. Weapons in disguise--activating mechanisms and protecting group chemistry in nature.
Kwan JC; Luesch H
Chemistry; 2010 Nov; 16(44):13020-9. PubMed ID: 20931575
[TBL] [Abstract][Full Text] [Related]
17. Structural optimization of a lysine demethylase 5 inhibitor for improvement of its cellular activity.
Terao M; Yamashita Y; Takada Y; Itoh Y; Suzuki T
Bioorg Med Chem; 2024 Jan; 98():117579. PubMed ID: 38168630
[TBL] [Abstract][Full Text] [Related]
18. Nanoarchitectonics: Complexes and Conjugates of Platinum Drugs with Silicon Containing Nanocarriers. An Overview.
Piorecka K; Kurjata J; Stanczyk WA
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502173
[TBL] [Abstract][Full Text] [Related]
19. Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines.
Gabano E; Pinton G; Balzano C; Boumya S; Osella D; Moro L; Ravera M
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443328
[TBL] [Abstract][Full Text] [Related]
20. A novel platinum complex containing a piplartine derivative exhibits enhanced cytotoxicity, causes oxidative stress and triggers apoptotic cell death by ERK/p38 pathway in human acute promyelocytic leukemia HL-60 cells.
Oliveira MS; Barbosa MIF; de Souza TB; Moreira DRM; Martins FT; Villarreal W; Machado RP; Doriguetto AC; Soares MBP; Bezerra DP
Redox Biol; 2019 Jan; 20():182-194. PubMed ID: 30359932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
